New drug combo shows promise for Tough-to-Treat liver cancer
NCT ID NCT04828486
First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 31 times
Summary
This study tested a combination of two drugs—futibatinib (which blocks cancer cell growth) and pembrolizumab (which helps the immune system attack cancer)—in 14 adults with advanced or spreading liver cancer that had not responded to prior treatment. The goal was to see if the combination could slow or stop the cancer from growing. While not a cure, this approach aims to give patients more time and control over their disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
Conditions
Explore the condition pages connected to this study.